menu
    • menu
    [{"orgOrder":0,"company":"Amivas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Artesunate","moa":"Malaria protein EXP-1","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Amivas","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Amivas \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amivas \/ Not Applicable"},{"orgOrder":0,"company":"Amivas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Artesunate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Amivas","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Amivas \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Amivas \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Amivas

    Menu

    Amivas

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Amivas

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Amivas

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Artesunate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AMIVAS Launches Europe’s First and Only Licensed Severe Malaria Treatment

                            Details : Artesunate Amivas (artesunate) for Injection is an antimalarial indicated for the initial treatment of severe malaria in adult and pediatric patients.

                            Brand Name : Artesunate Amivas

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 17, 2024

                            Lead Product(s) : Artesunate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Amivas

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Amivas

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Artesunate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AMIVAS Ireland Ltd. Receives Authorisation from the Medicines & Healthcare Products Regulatory Agency (MHRA) t...

                            Details : Studies examined a total of 6,886 patients and included adults, children and pregnant women. IV Artesunate reduced mortality by 34.7 percent and 22.5 percent compared with the injectable standard of care drug in the SEAQUMAT and AQUAMAT studies respectiv...

                            Brand Name : Artesunate-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 13, 2022

                            Lead Product(s) : Artesunate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth